Table 5.
NCA results for simulated profiles in healthy volunteers and CKD patients after administration of 510 mg ferumoxytol
| Group | Percentile | C max (µg/mL) | AUCinf (µg·h/mL) | AUC0–48h (µg·h/mL) | t ½ (h) |
|---|---|---|---|---|---|
| CKD haemodialysis | Median | 188 | 5,540 | 4,200 | 22.8 |
| 5th | 126 | 3,920 | 3,060 | 13.5 | |
| 95th | 309 | 8,080 | 5,930 | 38.5 | |
| CKD non-haemodialysis | Median | 204 | 5,920 | 4,700 | 20.1 |
| 5th | 140 | 4,190 | 3,460 | 12.4 | |
| 95th | 303 | 8,640 | 6,440 | 34.0 | |
| Healthy volunteers | Median | 209 | 5,980 | 4,770 | 19.9 |
| 5th | 145 | 4,280 | 3,560 | 12.0 | |
| 95th | 306 | 8,640 | 6,550 | 32.9 |
NCA non-compartmental analysis, CKD chronic kidney disease, C max maximum concentration, AUC inf area under the curve from time zero to infinity, AUC 0–48 area under the curve from time zero to 48 h, t ½ elimination half-life